블루아이병 백신 시장 규모 : 제품 유형별, 용도별, 지역별 범위 및 예측

Blue Eye Disease Vaccines Market Size And Forecast

Blue Eye Disease Vaccines Market size is valued at USD 3.2 Billion in 2024 and is projected to reach USD 6.24 Billion by 2032, growing at a CAGR of 3.93% during the forecast period 2026-2032.

The Blue Eye Disease is endemic in the central and west-central regions, which are the major swine-producing areas in tropical and subtropical areas, As a result of this, the potential for the growth of Blue Eye Disease vaccines in these endemic areas are higher, leading to the growth of the market. The Global Blue Eye Disease Vaccines Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Blue Eye Disease Vaccines Market Definition

Blue eye disease is a viral disease that occurs in nursing or growing pigs. Blue eye disease is caused by porcine rubulavirus. The disease is commonly identified by encephalitis, pneumonia, and respiratory diseases. Blue eye diseases are also connected to reproductive failure in adult pigs as well as corneal opacity, (eye disorder characterized by scarring of the cornea).

Although clinical symptoms and ulcers are a factor, they can be confused with other diseases. Several mechanisms have been developed to detect components of RNA, antibodies, and antigens. Two types of vaccines have been described with the Blue Eye Disease virus. Organic vaccines (monovalent and polyvalent) for use in horses, mules, and donkeys, are now available, as well as an ineffective, monovalent, serotype 4 vaccine, commercially available but no longer available. New vaccines, including subunits, have been tested.

Blue Eye Disease Vaccines aid patients suffering from different infections to improve overall operational efficiency as well as patient care. The high prevalence and incidence rates of hospital-acquired diseases increased focus on hygiene, and rising concerns over the spread of infectious diseases in both residential and commercial/industrial spaces/healthcare units, have led to an increase in patient flow to private clinics and hospitals. These factors, collectively, are projected to increase the demand for Blue Eye Disease Vaccines soon.

Over the past two decades, the Blue Eye Disease Vaccines Market has grown at an enormous scale, and over time it has brought many challenges with the change in the structure of the company and the way employees behave. The global Blue Eye Disease Vaccines Market is undergoing significant changes, as the manufacturers need to evolve in an attempt to keep the structure of their work.

Global Blue Eye Disease Vaccines Market Overview

The Blue Eye Disease is endemic in the central and west-central regions, which are the major swine-producing are in tropical and subtropical areas, As a result of this, the potential for the growth of Blue Eye Disease vaccines in these endemic areas are higher, leading to the growth of the market. Opportunities in the market include increasing awareness and a rise in expenditure on veterinary care in developing regions. These factors, collectively, are projected to increase the demand for Blue Eye Disease Vaccines shortly.

Increasing investment in R&D programs for the development of several preventive vaccines and guidelines provided by regulatory bodies associated with species health for Blue Eye Disease treatment are the major factors expected to stimulate the global Blue Eye Disease Vaccines Market. Developing technologically advanced healthcare infrastructure and ongoing research projects in association with international universities and prominent vendors for the development of effective vaccines will provide lucrative growth opportunities to the global Blue Eye Disease Vaccines Market.

However, the global Blue Eye Disease Vaccines Market faces challenges as a large percentage of the global population predominantly in developing economies is yet to have its hands on these vaccines. With the increase in the number of foreign travelers, cross migrations and other travels all over the world, including a growing population there is a need for the widespread manufacturing of these vaccines. However, the high costs associated with the operation and maintenance of facilities in the sector will be a hindrance to the growth of the market. In addition, the lack of qualified specialists will challenge the growth of the market.

Excess of unstructured data is expected to slow economic growth. The increasing complexity of interconnecting electronic components, the drop in global commodity prices, and the recent outbreak of COVID-19 have brought up many challenges to the Blue Eye Disease Vaccines Market. Nevertheless, rising demand for networking and storage devices in the data center, demand for smart healthcare infrastructure, robotics in healthcare applications, and sensor-based devices are expected to provide huge opportunities for the Blue Eye Disease Vaccines Market for the forecasted period.

Global Blue Eye Disease Vaccines Market: Segmentation Analysis

The Global Blue Eye Disease Vaccines Market is Segmented on the basis of Product Type, Application, and Geography.

Blue Eye Disease Vaccines Market, By Product Type

• Live Vaccines
• Killed Vaccines

Based on the Product Type, the market is segmented into Live Vaccines and Killed Vaccines. Live Vaccines are those vaccines in which the virus-causing disease is weakened and slowly develops body immunity. Killed Vaccines or Inactivated vaccines have grown viruses, bacteria, or pathogens which are then killed to stop the disease-producing agent.

Blue Eye Disease Vaccines Market, By Application

• Piglets
• Adult Pigs

Based on Application, the market is segmented into Piglets and Adult Pigs. Piglets are the largest contributor to the global market in 2019 in this segment and are very likely to continue the trend in the forecast period.

Blue Eye Disease Vaccines Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on regional analysis, the Global Blue Eye Disease Vaccines Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The North American region dominated the global market in 2019 followed by Europe and is expected to continue the trend in the forecast period. The Asia Pacific region is expected to grow at a rapid pace in the forecast period owing to rapid urbanization and industrialization with an increased investment towards smart & efficient technology and increased per capita income.

Key Players

The "Global Blue Eye Disease Vaccines Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as CAHIC, Merial, MSD Animal Health, Chopper Biology, Ceva, ChengDu Tecbond, Veterinary, Ringpu Biology, Qilu Animal and DHN.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BLUE EYE DISEASE VACCINES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BLUE EYE DISEASE VACCINES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BLUE EYE DISEASE VACCINES MARKET, BY Product Type

• 5.1 Overview
• 5.2 Live Vaccines
• 5.3 Killed Vaccines

6 GLOBAL BLUE EYE DISEASE VACCINES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Piglets
• 6.3 Adult Pigs

7 GLOBAL BLUE EYE DISEASE VACCINES MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East & Africa

8 GLOBAL BLUE EYE DISEASE VACCINES MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 CAHIC
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Merial
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 MSD Animal Health
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Chopper Biology
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Ceva
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 ChengDu Tecbond
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Veterinary
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Ringpu Biology
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Qilu Animal
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 DHN
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 Appendix

• 10.1 Related Research